BioNTech SE - ADR vs SAP SE — how do they compare? BioNTech SE - ADR trades at $92.57 (market cap $23.31B), while SAP SE trades at $203.34 (market cap $240.81B). The key difference: SAP SE is far larger — about 10.3× BioNTech SE - ADR's market cap, and SAP SE pays a 1.4% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SAP | |
|---|---|---|
Market Cap | $23.31B | $240.81B |
Sector | Health | Technology |
52-Week High | $119.34 | $280.46 |
52-Week Low | $83.89 | $146.38 |
Enterprise Value | $6.60B | $239.52B |
Dividend Yield | — | 1.4% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
SAP trades at $208.55, up 1.16% today, near its consensus price target of $209.67. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but revenue grew, driven by cloud demand. The company maintains robust profitability with a net income margin of 20.41% and solid cash flow from operations of $9.16B in 2025.
Outlook is mixed: AI and cloud growth offer upside, but profit guidance cuts and execution risks pose challenges. Analysts are generally bullish (53.49% buy ratings), yet investors should weigh high valuation multiples against competitive pressures in enterprise software. Near-term resistance lies at $211.
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →